Abstract: The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).

Abstract: A method and information handling system configured to obtain legacy client information handling system performance data of a legacy client information handling system, to identify legacy client information handling system performance constraints, to receive legacy client information handling system configuration parameter values, information handling system configuration parameter values comprising motherboard configuration parameter values and component configuration parameter values, to identify replacement client information handling system performance enhancements relative to the legacy client information handling system performance constraints based on improved replacement client information handling system capabilities and capacities relative to legacy client information handling system capabilities and capacities, to determine replacement client information handling system configuration parameter values based on the legacy client information handling system configuration parameter values and the repla

Abstract: Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I).

Abstract: An image sensor having global shutter circuitry and an extremely fine pixel pitch. Disclosed image sensors combine global shutter circuitry with rolling shutter circuitry for respective subsets of sensor pixels to marry imaging benefits of global shutter circuitry with relatively small circuit overhead of rolling shutter circuitry. Such image sensors can achieve improved optical performance with smaller pixel pitch and optical resolution than existing global shutter image sensors.

Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Abstract: An information handling system includes a primary integrated display device housing and a second integrated display device housing attached via a hinge and a processor to determine a first relative orientation of the primary integrated display device housing to the second integrated display device housing from a plurality of orientation sensors. The processor further determines a working software application context by detecting at least a first software application running on the information handling system wherein the working software application context further includes an operating state rank of the first software application relative to other software applications.

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

Abstract: A method and information handling system configured to obtain legacy client information handling system performance data of a legacy client information handling system, to identify legacy client information handling system performance constraints, to receive legacy client information handling system configuration parameter values, information handling system configuration parameter values comprising motherboard configuration parameter values and component configuration parameter values, to identify replacement client information handling system performance enhancements relative to the legacy client information handling system performance constraints based on improved replacement client information handling system capabilities and capacities relative to legacy client information handling system capabilities and capacities, to determine replacement client information handling system configuration parameter values based on the legacy client information handling system configuration parameter values and the repla

Abstract: A method and information handling system for obtaining information handling system wear parameter values representative of wear of the information handling system, the information handling system wear parameter sensors comprising a motherboard event wear parameter sensor for obtaining motherboard event wear parameter values, a component event wear parameter sensor for obtaining component event wear parameter values, and a usage wear parameter sensor for obtaining usage wear parameter values, for calculating client information handling system wear based on the information handling system wear parameter values and the statistical model of wear estimation, and for providing a service life indication for the client information handling system, the service life indication indicative of a disposition suitability.

Abstract: An information handling system includes an application processor that executes instructions of an intelligent energy management system that determines energy demand estimation based on component device utilization data from a group of client information handling systems. The information handling system includes a power policy engine that determines a timeseries power cost estimation based on the energy demand estimation, day and time of energy usage, and energy rate for the time and location.

Abstract: An information handling system includes a primary integrated display device and a second integrated display device attached via a hinge and a processor. The processor determines a first relative orientation of the primary integrated display device to the second integrated display device from orientation sensors. The processor further determines a working software application context by detecting at least a first software application running on the information handling system wherein the working software application context further includes an operating state rank of the first software application relative to other software applications.

Abstract: An information handling system includes an application processor that executes instructions of an intelligent energy management system that determines energy demands for an enterprise, application processor determines a statistical model of power demand estimation for a client in the enterprise. The information handling system includes a network adapter that receives component device utilization data from client, and includes a memory device that stores component device utilization data received from the client. The application processor determines power consumption for component devices across the enterprise that has the client for use in the statistical model of consumed power.

Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.